{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:56:19Z","timestamp":1762005379012,"version":"build-2065373602"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.108969","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T06:37:12Z","timestamp":1655707032000},"page":"108969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces"],"prefix":"10.1016","volume":"110","author":[{"given":"Priyanka H.","family":"Mazire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.108969_b0005","unstructured":"WHO- Global Health Observatory, Leishmaniasis [Available from: https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/gho-ntd-leishmaniasis] Accessed on 02 September, 2021."},{"key":"10.1016\/j.intimp.2022.108969_b0010","first-page":"1","article-title":"A Review of Leishmaniasis: Current Knowledge and Future Directions","author":"Mann","year":"2021","journal-title":"Curr. Trop Med. Rep."},{"issue":"10","key":"10.1016\/j.intimp.2022.108969_b0015","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/14656566.2019.1609940","article-title":"Current and emerging medications for the treatment of leishmaniasis","volume":"20","author":"Chakravarty","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.intimp.2022.108969_b0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00281-020-00788-y","article-title":"Leishmaniasis immunopathology\u2014impact on design and use of vaccines, diagnostics and drugs","volume":"42","author":"Kaye","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.intimp.2022.108969_b0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jim.2015.04.022","article-title":"Uncovering Leishmania-macrophage interplay using imaging flow cytometry","volume":"423","author":"Terrazas","year":"2015","journal-title":"J. Immunol. Methods."},{"key":"10.1016\/j.intimp.2022.108969_b0030","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.biopha.2018.06.167","article-title":"Immunomodulatory effect of Arabinosylated lipoarabinomannan restricts the progression of visceral leishmaniasis through NOD2 inflammatory pathway: Functional regulation of T cell subsets","volume":"106","author":"Jawed","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2022.108969_b0035","first-page":"155320","article-title":"Cytokines in the immunity and immunopathogenesis in leishmaniasis","author":"Saha","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2022.108969_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109098","article-title":"Functional aspects of T cell diversity in visceral leishmaniasis","volume":"117","author":"Jawed","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2022.108969_b0045","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41598-020-60435-2","article-title":"Leishmania donovani infection induces differential miRNA expression in CD4+ T cells","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.108969_b0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2010.01.004","article-title":"Notch signaling in the immune system","volume":"32","author":"Radtke","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108969_b0055","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.4049\/jimmunol.164.4.2001","article-title":"TGF-\u03b2 mediates CTLA-4 suppression of cellular immunity in murine kalaazar","volume":"164","author":"Gomes","year":"2000","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108969_b0060","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12659","article-title":"Leishmania infantum induces expression of the negative regulatory checkpoint, CTLA-4, by human naive CD8 (+) T cells","volume":"41","author":"Viana","year":"2019","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0065","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4049\/jimmunol.0902206","article-title":"CD40 expression levels modulate regulatory T cells in Leishmania donovani infection","volume":"185","author":"Martin","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cyto.2018.07.001","article-title":"The impact of IL-10 dynamic modulation on host immune response against visceral leishmaniasis","volume":"112","author":"Mesquita","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2022.108969_b0075","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/eji.200324021","article-title":"Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani","volume":"34","author":"Zubairi","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0080","doi-asserted-by":"crossref","first-page":"6453","DOI":"10.1128\/IAI.71.11.6453-6462.2003","article-title":"Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis","volume":"71","author":"Murray","year":"2003","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.intimp.2022.108969_b0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0035-9203(03)90167-2","article-title":"Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline","volume":"97","author":"Rijal","year":"2003","journal-title":"Trans. R Soc. Trop Med. Hyg."},{"year":"2010","series-title":"Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Vol. 949","key":"10.1016\/j.intimp.2022.108969_b0090"},{"issue":"7","key":"10.1016\/j.intimp.2022.108969_b0095","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/molecules14072317","article-title":"Pentavalent\u0301 antimonials: new perspectives for old drugs","volume":"14","author":"Frezard","year":"2009","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.intimp.2022.108969_b0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00430-003-0201-2","article-title":"Miltefosine (Impavido): the first oral treatment against leishmaniasis","volume":"193","author":"Sindermann","year":"2004","journal-title":"Med. Microbiol. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108969_b0105","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/cid\/cit508","article-title":"One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India","volume":"57","author":"Burza","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2022.108969_b0110","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"25","key":"10.1016\/j.intimp.2022.108969_b0115","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.108969_b0120","series-title":"PLoSNegl Trop Dis.","first-page":"e709","article-title":"Geographical variation in the response of Visceral Leishmaniasis to Paromomycin in East Africa: a multicentre, open-label, randomized trial","volume":"4(10)","author":"Hailu","year":"2010"},{"issue":"10","key":"10.1016\/j.intimp.2022.108969_b0125","article-title":"Paromomycin for the treatment of Visceral Leishmaniasis in Sudan: a randomized, open-label, dose-finding study. Lockwood DNJ, editor","volume":"4","author":"Musa","year":"2010","journal-title":"PLoSNegl Trop Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.108969_b0130","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/tmi.12238","article-title":"Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?","volume":"19","author":"Salih","year":"2014","journal-title":"Trop Med. Int. Heal."},{"issue":"1","key":"10.1016\/j.intimp.2022.108969_b0135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40249-018-0491-7","article-title":"Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis","volume":"7","author":"Gebreyohannes","year":"2018","journal-title":"Infect. Dis. Poverty."},{"key":"10.1016\/j.intimp.2022.108969_b0140","unstructured":"Pan American Health Organization. Leishmaniasis in the Americas: treatment recommendations. Washington D.C.: PAHO; 2018. http:\/\/iris.paho.org."},{"issue":"10","key":"10.1016\/j.intimp.2022.108969_b0145","article-title":"Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India","volume":"12","author":"Goyal","year":"2018","journal-title":"PLoSNegl Trop Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.108969_b0150","article-title":"Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial","volume":"11","author":"Romero","year":"2017","journal-title":"PLoSNegl Trop Dis."},{"key":"10.1016\/j.intimp.2022.108969_b0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4049\/jimmunol.177.1.22","article-title":"Cutting edge: STAT1 and T-bet play distinct roles in determining outcome of visceral leishmaniasis caused by Leishmania donovani","volume":"177","author":"Rosas","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0160","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.4049\/jimmunol.1003588","article-title":"IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis","volume":"186","author":"Ansari","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fcimb.2018.00181","article-title":"Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis","volume":"8","author":"Kip","year":"2018","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.intimp.2022.108969_b0170","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1258\/0049475054036887","article-title":"Adenosine deaminase activity in sera of patients with visceral leishmaniasis in Nepal","volume":"35","author":"Baral","year":"2005","journal-title":"Trop Doct."},{"issue":"1","key":"10.1016\/j.intimp.2022.108969_b0175","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12797","article-title":"Biomarkers of the early response to treatment of visceral leishmaniasis: A prospective cohort study","volume":"43","author":"Lima","year":"2021","journal-title":"Parasite Immunol."},{"issue":"37","key":"10.1016\/j.intimp.2022.108969_b0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1590\/S0100-879X2004000100018","article-title":"Serum cytokine profile in the subclinical form of visceral leishmaniasis","volume":"2004","author":"Gama","year":"2004","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.intimp.2022.108969_b0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2334-5-113","article-title":"Balance of IL-10 and interferon-\u03b3 plasma levels in human visceral leishmaniasis: implications in the pathogenesis","volume":"5","author":"Caldas","year":"2005","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108969_b0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clim.2006.11.008","article-title":"Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome","volume":"122","author":"Ansari","year":"2007","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0195","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10096-013-1999-1","article-title":"Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment","volume":"33","author":"Duthie","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108969_b0200","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/314635","article-title":"Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis","volume":"179","author":"Sang","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108969_b0205","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2249.1995.tb03849.x","article-title":"Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis","volume":"102","author":"Schriefer","year":"1995","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108969_b0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1469-0691.2000.00011.x","article-title":"Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-\u03b1 in patients with visceral leishmaniasis","volume":"2000","author":"Medeiros","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.intimp.2022.108969_b0215","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/0035-9203(95)90442-5","article-title":"Acute phase protein concentrations predict parasite clearance rate during therapy for visceral leishmaniasis","volume":"89","author":"Wasunna","year":"1995","journal-title":"Trans. R Soc. Trop Med. Hyg."},{"key":"10.1016\/j.intimp.2022.108969_b0220","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12875","article-title":"Antileishmanial potential of immunomodulator gallic acid against experimental murine visceral leishmaniasis","author":"Keshav","year":"2021","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0225","doi-asserted-by":"crossref","first-page":"6671287","DOI":"10.1155\/2021\/6671287","article-title":"Related Pentacyclic Triterpenes Have Immunomodulatory Activity in Chronic Experimental Visceral Leishmaniasis","volume":"2021","author":"de Jesus","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.intimp.2022.108969_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107291","article-title":"Synergic effect of eugenol oleate with amphotericin B augments anti-leishmanial immune response in experimental visceral leishmaniasis in vitro and in vivo","volume":"91","author":"Kar","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108969_b0235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/dkaa406","article-title":"Antileishmanial effect of the natural immunomodulator genipin through suppression of host negative regulatory protein UCP2","volume":"76","author":"Gupta","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.intimp.2022.108969_b0240","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12952","article-title":"Barley beta-Glucan and Zymosan induce Dectin-1 and Toll-like receptor 2 co-localization and anti-leishmanial immune response in Leishmania donovani-infected BALB\/c mice","volume":"92","author":"Patidar","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2020.107948","article-title":"Immunomodulator mediated changes in plasma membrane calcium ATPase in controlling visceral leishmaniasis","volume":"217","author":"Roy","year":"2020","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.intimp.2022.108969_b0250","article-title":"Antileishmanial activity and immunomodulatory effect of secosubamolide, a butanolide isolated from Nectandra oppositifolia (Lauraceae)","volume":"25","author":"da Costa-Silva","year":"2019","journal-title":"J. Venom Anim. Toxins Incl. Trop. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.108969_b0255","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ijantimicag.2017.04.022","article-title":"Antileishmanial and immunomodulatory activities of lupeol, a triterpene compound isolated from Sterculia villosa","volume":"50","author":"Das","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2022.108969_b0260","article-title":"Evidence for Reversal of Immunosuppression by Homeopathic Medicine to a Predominant Th1-type Immune Response in BALB\/c Mice Infected with Leishmania donovani","author":"Joshi","year":"2021","journal-title":"Homeopathy."},{"key":"10.1016\/j.intimp.2022.108969_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155301","article-title":"Oral administration of eugenol oleate cures experimental visceral leishmaniasis through cytokines abundance","volume":"145","author":"Charan Raja","year":"2021","journal-title":"Cytokine."},{"key":"10.1016\/j.intimp.2022.108969_b0270","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2019.00670","article-title":"Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy","volume":"10","author":"Dayakar","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004415","article-title":"Combined immune therapy for the treatment of visceral leishmaniasis","volume":"10","author":"Faleiro","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.intimp.2022.108969_b0280","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1038\/s41598-017-15288-7","article-title":"Leptin regulates granzyme-A, PD-1 and CTLA-4 expression in T cell to control visceral leishmaniasis in BALB\/c mice","volume":"7","author":"Dayakar","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2022.108969_b0285","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/tropicalmed7040054","article-title":"Immune Responses in Leishmaniasis: An Overview","volume":"7","author":"Costa-da-Silva","year":"2022","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108969_b0290","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3389\/fimmu.2018.02529","article-title":"Macrophage Polarization in Leishmaniasis: Broadening Horizons","volume":"9","author":"Tomiotto-Pellissier","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0295","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during Visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasites Vectors"},{"issue":"1","key":"10.1016\/j.intimp.2022.108969_b0300","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12603","article-title":"Metabolic regulation of macrophage phenotype and function","volume":"280","author":"Saha","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2022.108969_b0305","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/796235","article-title":"Peroxisome proliferator-activated receptor\u03b3-mediated polarization of macrophages in Leishmania infection","volume":"2012","author":"Chan","year":"2012","journal-title":"PPAR Res."},{"key":"10.1016\/j.intimp.2022.108969_b0310","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12586","article-title":"Leishmania infection activates host mTOR for its survival by M2 macrophage polarization","volume":"40","author":"Kumar","year":"2018","journal-title":"Parasit. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0315","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1128\/IAI.00184-15","article-title":"Genetically modified live attenuated Leishmania donovani parasites induce innate immunity through classical activation of macrophages that direct the Th1 response in mice","volume":"83","author":"Bhattacharya","year":"2015","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2022.108969_b0320","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fcimb.2018.00197","article-title":"Transcriptional profiling of immune-related genes in Leishmania infantum-infected mice: identification of potential biomarkers of infection and progression of disease","volume":"8","author":"Ontoria","year":"2018","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108969_b0325","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/infdis\/170.3.659","article-title":"Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma","volume":"170","author":"Sundar","year":"1994","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.108969_b0330","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin. Transl. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108969_b0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third-generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"issue":"8","key":"10.1016\/j.intimp.2022.108969_b0340","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00436-020-06752-x","article-title":"Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells","volume":"119","author":"Ribeiro","year":"2020","journal-title":"Parasitol Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.108969_b0345","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/IAI.00611-07","article-title":"gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB\/c mice infected with Leishmania donovani","volume":"76","author":"Bhowmick","year":"2008","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.intimp.2022.108969_b0350","first-page":"197","article-title":"Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS","volume":"12","author":"Mastroianni","year":"2004","journal-title":"Infez. Med."},{"key":"10.1016\/j.intimp.2022.108969_b0355","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijbiomac.2015.04.043","article-title":"Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response","volume":"79","author":"Chaurasia","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"issue":"17","key":"10.1016\/j.intimp.2022.108969_b0360","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1111\/bph.12754","article-title":"Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responses","volume":"171","author":"Kansal","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"8845826","key":"10.1016\/j.intimp.2022.108969_b0365","article-title":"A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis","volume":"2021","author":"Ratnapriya","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.intimp.2022.108969_b0370","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/tmi.13382","article-title":"Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy","volume":"25","author":"Velez","year":"2020","journal-title":"Trop Med. Int. Health."},{"key":"10.1016\/j.intimp.2022.108969_b0375","first-page":"1","article-title":"Designing of a Novel Fusion Protein Vaccine Candidate Against Human Visceral Leishmaniasis (VL) Using Immunoinformatics and Structural Approaches","author":"Atapour","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2022.108969_b0380","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/513439","article-title":"HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages","volume":"195","author":"Basu","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"35","key":"10.1016\/j.intimp.2022.108969_b0385","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1016\/j.vaccine.2008.05.091","article-title":"Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells","volume":"26","author":"Resende","year":"2008","journal-title":"Vaccine."},{"issue":"11","key":"10.1016\/j.intimp.2022.108969_b0390","article-title":"Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response","volume":"4","author":"Nico","year":"2010","journal-title":"PLoSNegl Trop Dis."},{"issue":"33","key":"10.1016\/j.intimp.2022.108969_b0395","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1016\/j.vaccine.2017.06.013","article-title":"Wilson ME.CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination","volume":"35","author":"Christiaansen","year":"2017","journal-title":"Vaccine."},{"issue":"8","key":"10.1016\/j.intimp.2022.108969_b0400","doi-asserted-by":"crossref","first-page":"e0009627","DOI":"10.1371\/journal.pntd.0009627","article-title":"Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis","volume":"15","author":"Helou","year":"2021","journal-title":"PLoSNegl Trop Dis."},{"issue":"11","key":"10.1016\/j.intimp.2022.108969_b0405","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.3390\/microorganisms9112253","article-title":"Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant","volume":"9","author":"Fern\u00e1ndez","year":"2021","journal-title":"Microorganisms."},{"key":"10.1016\/j.intimp.2022.108969_b0410","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molimm.2021.11.009","article-title":"Immunological characterization of rLdTCP1gamma for its prophylactic potential against visceral leishmaniasis in hamster model","volume":"141","author":"Anand","year":"2022","journal-title":"Mol. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108969_b0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007880","article-title":"Immunogenicity and Efficacy of Single Antigen Gp63, Polytope and PolytopeHSP70 DNA Vaccines against Visceral Leishmaniasis in Experimental Mouse Model","volume":"4","author":"Sachdeva","year":"2009","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.intimp.2022.108969_b0420","first-page":"383","article-title":"Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB-CTE Antigens against Visceral Leishmaniasis in Syrian Hamster as Preliminary Study","volume":"15","author":"Taslimi","year":"2020","journal-title":"Iran J Parasitol."},{"issue":"234","key":"10.1016\/j.intimp.2022.108969_b0425","doi-asserted-by":"crossref","first-page":"234ra256","DOI":"10.1126\/scitranslmed.3008222","article-title":"Modular multi-antigen T cell epitope-enriched DNA vaccine against human leishmaniasis","volume":"6","author":"Das","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2022.108969_b0430","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/vaccines8010141","article-title":"Subcutaneous Immunization of Leishmania HSP70-II Null Mutant Line Reduces the Severity of the Experimental Visceral Leishmaniasis in BALB\/c Mice","volume":"8","author":"Solana","year":"2020","journal-title":"Vaccines."},{"issue":"8","key":"10.1016\/j.intimp.2022.108969_b0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003091","article-title":"Combining Cationic Liposomal Delivery with MPL-TDM for Cysteine Protease Cocktail Vaccination against Leishmania donovani: Evidence for Antigen Synergy and Protection","volume":"8","author":"Das","year":"2014","journal-title":"PLOS Neg Trop Dis."},{"key":"10.1016\/j.intimp.2022.108969_b0440","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s13071-020-04243-7","article-title":"Cytokine profile and nitric oxide levels in peritoneal macrophages of BALB\/c mice exposed to the fucose-mannose ligand of Leishmania infantum combined with glycyrrhizin","volume":"13","author":"Namdar Ahmadabad","year":"2020","journal-title":"Parasites Vectors."},{"key":"10.1016\/j.intimp.2022.108969_b0445","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/microorganisms8081201","article-title":"Leishmania Immunity: Advancing Immunotherapy and Vaccine Development","volume":"8","author":"Ikeogu","year":"2020","journal-title":"Microorganisms."},{"issue":"19","key":"10.1016\/j.intimp.2022.108969_b0450","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2011.02.096","article-title":"A clinical trial to evaluate the safety and immunogenicity of Leish-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis","volume":"29","author":"Chakravarty","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.intimp.2022.108969_b0455","doi-asserted-by":"crossref","unstructured":"Pedro Cecilio, Fabiano Oliveira, Anabela Cordeiro da Silva, Vaccines for human Leishmaniasis: Where do we stand and what is still missing? 2018. https:\/\/doi.org\/10.5772\/intechopen.75000.","DOI":"10.5772\/intechopen.75000"},{"key":"10.1016\/j.intimp.2022.108969_b0460","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00436-005-0008-8","article-title":"Intramuscular immunization with p36 (LACK) DNA vaccine induces IFN-c production but does not protect BALB\/c mice against Leishmania chagasi intravenous challenge","volume":"98","author":"Marques-Da-Silva","year":"2005","journal-title":"Parasitol Res."},{"key":"10.1016\/j.intimp.2022.108969_b0465","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.4049\/jimmunol.0900132","article-title":"Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani","volume":"183","author":"Sharma","year":"2009","journal-title":"J Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108969_b0470","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/gt.2015.35","article-title":"Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine","volume":"22","author":"Riede","year":"2015","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.108969_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2021.104884","article-title":"Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis","volume":"24","author":"Gomes","year":"2022","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2022.108969_b0480","doi-asserted-by":"crossref","first-page":"043","DOI":"10.3389\/fimmu.2018.01043","article-title":"Peptide vaccines for Leishmaniasis","volume":"9","author":"De Brito","year":"2018","journal-title":"Front. Immun."},{"issue":"3","key":"10.1016\/j.intimp.2022.108969_b0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230381","article-title":"The immunogenicity and protective immunity of multi-epitopes DNA prime-protein boost vaccines encoding Amastin-Kmp-11, Kmp11- Gp63 and Amastin-Gp63 against visceral leishmaniasis","volume":"15","author":"Zhang","year":"2020","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.intimp.2022.108969_b0490","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/20477724.2020.1842976","article-title":"Design of a multi-epitope subunit vaccine for immune-protection against Leishmania parasite","volume":"114","author":"Yadav","year":"2020","journal-title":"Pathog Glob Health."},{"key":"10.1016\/j.intimp.2022.108969_b0495","first-page":"11:817","article-title":"Leishmania-Specific Promiscuous Membrane Protein Tubulin Folding Cofactor D Divulges Th1\/Th2 Polarization in the Host via ERK-1\/2 and p38 MAPK Signaling Cascade","author":"Jamal","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108969_b0500","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.micinf.2017.03.002","article-title":"Immuno-informatics-based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects","volume":"19","author":"Mahantesh","year":"2017","journal-title":"Microbes Infect."},{"issue":"1","key":"10.1016\/j.intimp.2022.108969_b0505","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1756-3305-4-150","article-title":"Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation","volume":"4","author":"Carri\u00f3n","year":"2011","journal-title":"Parasites Vectors"},{"issue":"1","key":"10.1016\/j.intimp.2022.108969_b0510","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.1700674","article-title":"Live Attenuated Leishmania donovani Centrin Gene-Deleted Parasites Induce IL-23-Dependent IL-17-Protective Immune Response against Visceral Leishmaniasis in a Murine Model","volume":"200","author":"Banerjee","year":"2018","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.108969_b0515","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.315","article-title":"DDX3 DEAD-box RNA helicase plays a central role in mitochondrial protein quality control in Leishmania","volume":"7","author":"Padmanabhan","year":"2016","journal-title":"Cell Death Dis."},{"issue":"24","key":"10.1016\/j.intimp.2022.108969_b0520","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.vaccine.2019.04.068","article-title":"Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB\/c mice","volume":"37","author":"Elikaee","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.intimp.2022.108969_b0525","first-page":"835","article-title":"Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB\/c mice","volume":"6","author":"Danesh-Bahreini","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.intimp.2022.108969_b0530","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3389\/fimmu.2017.00684","volume":"8","author":"Athanasiou","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108969_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111920","article-title":"Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis - A review","volume":"141","author":"Prasanna","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.intimp.2022.108969_b0540","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/pim.12042","article-title":"Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice","volume":"35","author":"Saljoughian","year":"2013","journal-title":"Parasite Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:58:57Z","timestamp":1761587937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922004532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":108,"alternative-id":["S1567576922004532"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108969","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108969"}}